首页> 外文OA文献 >PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer

【2h】

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer

机译：PTPRF表达作为厄洛替尼治疗非小细胞肺癌的潜在预后/预测指标

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Soulières Denis; Hirsch Fred R.; Shepherd Frances A.; Bordogna Walter; Delmar Paul; Shames David S.; Klughammer Barbara;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer [J] . Soulieres Denis, Hirsch Fred R., Shepherd Frances A., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第9期

机译：PTPRF表达作为厄洛替尼治疗非小细胞肺癌的潜在预后/预测标记。
2. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases. [J] . Benlloch S, Galbis-Caravajal JM, Alenda C, Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第1期

机译：I期非小细胞肺癌（NSCLC）切除的纵隔淋巴结中分子标志物的表达：预后的影响和潜在的隐匿性微转移标志物的作用。
3. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases [J] . S. Benlloch1*† J. M. Galbis-Caravajal5 C. Alenda2 F. M. Peiró2 M. Sanchez-Ronco6 J. M. Rodríguez-Paniagua3 B. Baschwitz3 E. Rojas1 and B. Massutí4 Annals of Oncology . 2009,第1期

机译：切除的I期非小细胞肺癌（NSCLC）纵隔淋巴结中分子标志物的表达：预后的影响和潜在的隐匿性微转移标志物的作用
4. PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS [C] . Jun Adachi, Yuichi Abe, Maiko Nagano, International Mass Spectrometry Conference . 2018

机译：用厄洛替尼处理的非小细胞肺癌细胞的磷脂蛋白酶揭示了耐药象征和潜在目标
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer [O] . Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, -1

机译：BIM和mTOR表达水平可预测EGFR突变型非小细胞肺癌埃罗替尼的疗效
7. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer [O] . Mok Tony, Ladrera Guia, Srimuninnimit Vichien, 2016

机译：安慰剂对照FASTACT-2Ⅲ期研究在晚期非小细胞肺癌一线治疗中联合厄洛替尼联合吉西他滨/铂的肿瘤标志物分析

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅